Slide 1: Investor Presentation Q2 & H1FY24
Manking|i> INVESTOR PRESENTATION Q2 & HIFY24 31st October 2023
Slide 2: Safe Harbour Statement
Safe Harbour Statement The statements, are as on date and may contain forward-looking statements like the words “believe”, “expects”, “anticipate”, “aim”, “will likely result”, “would”, “will continue”, “contemplate” “intends”, “plans”, “estimates”, “seek to”, “future”, “objective”, “projects”, “goa
Slide 3: Index
Index 01 Corporate Framework 03 Business Updates • Mankind at a Glance • Domestic Business • Key Strengths • Consumer Healthcare Business • Strategy Going Ahead • Export Business 02 Financial Performance 04 Additional Information • Key Performance Indicators – H1FY24 • Key Financials – Q2FY24 • Envi
Slide 4: Corporate Framework
ng Mankindlil> Serving Life Corporate Framework
Slide 5: Mankind Pharma at a Glance
Mankind Pharma at a Glance #1 Youngest #4 4 Rank in Prescriptions Consumer Healthcare brands in Top 5 of the IPM* By value in the IPM* Market over the last five years* ranked #1 in their categories* Leadership INR 8,749 Crore 97% 22 15,000+ FY23 Revenue Domestic Revenue brands* worth INR 100 Cr+ Fie
Slide 6: Key Strengths
Key Strengths India revenues contribute 97% of revenues in FY23 Focus on Focus on 75% of manufacturing in-house; track record of domestic Strong In- domestic innovation with commercialization of business Volume- house business “Dydrogesterone” manufacturing growth driven Avg. Volume growth of 3x in
Slide 7: Strategy Going Ahead
Strategy Going Ahead Increase the value of prescriptions in existing markets of strength by expanding market coverage; CVM moved from 62% in FY21 to 68% in FY23* Increasing share of chronic segment by growing presence in existing therapies (Diabetes - Insulin Glargine, Respiratory - Inhalers) and ex
Slide 8: Financial Performance
Cig Mankindil> Serving Life Financial Performance
Slide 9: Q2FY24 - Key Financial Snapshot
Q2FY24 - Key Financial Snapshot Financials / Capital Growth Margins Efficiency 2,708 11.6% 28.5% Revenue (INR Cr) YoY Growth ROCE* 686 / 25.3% 15.4% 24.3% EBITDA (INR Cr)/Margin YoY Growth ROE* Mr. Rajeev Juneja 511 / 18.9% 21.0% Vice Chairman & Managing Director PAT (INR Cr)/Margin YoY Growth • “ W
Slide 10: Q2 & H1 FY24 - P&L Highlights
Q2 & H1 FY24 - P&L Highlights YoY QoQ YoY INR Crore Q2FY24 Q2FY23 Q1FY24 H1FY24 H1FY23 Growth Growth Growth Revenue from Operations 2,708 2,425 11.6% 2,579 5.0% 5,287 4,605 14.8% (A=B+C) Domestic Business (B) 2,529 2,356 7.3% 2,419 4.6% 4,948 4,485 10.3% Consumer Healthcare 193 190 1.6% 208 (7.2%) 4
Slide 11: Key Financial Metrics
Key Financial Metrics ROE* ROCE* Net Cash# (INR crore) Dip on account Dip on account 34% of acquisition of acquisition 28% 24% 24% 23% 2,159 23% 31% 25% 1,366 642 412 FY22 FY23 Q2FY23 Q2FY24 FY22 FY23 Q2FY23 Q2FY24 FY22 FY23 Q2FY23 Q2FY24 Cash Flow from Operations (INR crore) CAPEX (INR crore) Net O
Slide 12: Business Updates
ye Mankindil> Serving Life Business Updates
Slide 13: Domestic Business Performance
Domestic Business Performance Steady Growth in Domestic Revenue* Volumes declined due to delayed acute season INR Crore 16.7 8,453 7,595 9.7 2.6 2.1 -0.3 0.1 0.0 -4.6 2,356 2,529 FY22 FY23 Q2 FY23 Q2 FY24 FY22 FY23 Q2FY23 Q2FY24 IPM Growth Rate % Mankind Growth Rate % • Domestic Business witnessed a
Slide 14: Increasing Share of Chronic Segment
Increasing Share of Chronic Segment Increasing share of chronic segment having higher price realisation and lifetime value Consistent focus to increase chronic contribution In Q2FY24, Mankind registered 1.1x outperformance vs. IPM 3% 38 4% 37 37 19 36 1.0x 1.1x 14 34 34 13 11 11 11 33 10 9 32 FY22 F
Slide 15: Across a Fast Growing Diversified Portfolio
..Across a Fast Growing Diversified Portfolio High Ranks across Acute and Chronic Areas Q2FY24 - Performance of top 5 Therapies (cont. ~57% of sales) 14.9 Rank in CVM FY 20-23 CAGR Therapy Areas (Q2FY24) 10.2 Mankind IPM 9.4 8.4 7.0 6.9 Anti-Infectives 4 11% 8% 5.3 4.9 4.9 Cardiovascular 4 17% 11% 3
Slide 16: Building Fast Growing Consumer Healthcare Franchise
Building Fast Growing Consumer Healthcare Franchise… Consumer Healthcare Segment Revenue INR Crore 692 589 2% 190 193 FY22 FY23 Q2FY23 Q2FY24 • Consumer Healthcare segment witnessed muted growth during the quarter due to: • initiatives taken towards optimization of channel inventory • implementation
Slide 17: with Market Leading Brands
…with Market Leading Brands Dominant Brands in Consumer Healthcare #1 #1 #2 Condom Brand Pregnancy Test Kit Brand Antacid Powder Brand Market Share – 30% Market Share – 85% Market Share – 8% #9 #1 #1 Vitamins, Minerals, Nutrients Emergency Contraceptive Medicated Anti-Acne Brand Brand Brand Market S
Slide 18: Strong Corporate Identity Complements Brand Recall
Strong Corporate Identity Complements Brand Recall… Strategically selected national and regional brand ambassadors Corporate Brand Ambassadors Consumer Healthcare Brand Ambassadors Kartik Aaryan Sunny Leone Anushka Sharma Kajal Aggarwal Srabanti Chatterjee Paresh Rawal & Brahmanandam Biswanath Basu
Slide 19: With Targeted Marketing Initiatives
…With Targeted Marketing Initiatives #ApnePartnerSePucho Campaign - A 360-degree Campaign with Brand transitioned from being pregnancy detection brand to its Kartik Aaryan - Launched in August – extensive range to position as “Expert Pregnancy Care Partner” • Launched #ThankYouChemist AI revolutiona
Slide 20: With Targeted Marketing Initiatives
…With Targeted Marketing Initiatives Gas-O-Fast - India Ki Acidity Ka Asli Indian Solution HealthOK - To drive brand awareness & connect at regional level • Activity done in Pandharpur Yatra, Maharashtra; Nauchandi Mela, Meerut; • Ranveer Singh’s HealthOK campaign launched in 3 languages-Hindi, Mara
Slide 21: Exports Business Update
Exports Business Update Revenue from Exports INR Crore 296 187 179 69 FY22 FY23 Q2FY23 Q2FY24 • Exports business witnessed a growth of 159% YoY in Q2FY24 aided by certain one-off opportunities in the US • Focus on differentiated filings, including in-licensing for key markets • In addition to USA, t
Slide 22: Additional Information
Cig Mankindll> Serving Life yy Additional Information
Slide 23: Key Performance Indicators (as per ICDR Requirement post IPO)
Key Performance Indicators (as per ICDR Requirement post IPO) FY22 FY23 Q2FY23 Q2FY24 H1 FY23 H1 FY24 Revenue from Operations within India as a percentage of revenue 97.60% 96.62% 97.16% 93.39% 97.40% 93.59% from operations % EBITDA* (INR Million) 20,038.00 19,130.61 5,945 6,861 10,542 13,457 EBITDA
Slide 24: ESG: Organization wide focus on sustainable growth
ESG : Organization* wide focus on sustainable growth Key Key Key New Highlights Initiatives Priorities Technologies Conferred with Sustainability Impact Award – UBS Forums • Reduced fresh water • ESG assessment • Preparing for ESG • Sikkim- Paddle dryer for consumption by 22% YoY started for critica
Slide 25: H1FY24 Business Updates
H1FY24 Business Updates Consumer Healthcare Segment Strong Growth in Domestic Revenue Revenue from Exports (INR crore) Revenue (INR crore) 4,948 339 4,485 383 401 182% 120 H1FY23 H1FY24 H1FY23 H1FY24 H1FY23 H1FY24 1.4x outperformance to IPM chronic in Consistent focus to Volume recovery of 350 Bps Y
Slide 26: Key Performance Highlights
Key Performance Highlights Key Performance Highlights FY18 FY19 FY20 FY21 FY22 FY23 Value Growth YoY in IPM (%) 11.3 12.6 12.5 11.1 17.7 10.6 Market share by Value in IPM (%) 3.9 4.0 4.1 4.3 4.3 4.4 Market Ranking by Value in IPM (x) 4 4 4 4 4 4 CVM share in total IPM (%) 60.2 61.6 62.4 62.2 65.4 68
Slide 27: Sales Mix Trends
Sales Mix Trends Therapy wise share in Total Revenue FY18 FY19 FY20 FY21 FY22 FY23 ANTI-INFECTIVES 17.7 15.8 15.9 13.2 14.7 15.0 CARDIAC 10.1 10.8 11.5 12.6 12.1 12.8 GASTRO INTESTINAL 12.3 11.5 11.4 11.3 10.9 10.8 RESPIRATORY 7.6 8.0 8.7 7.2 9.7 9.5 PAIN / ANALGESICS 6.0 6.4 6.1 5.4 5.4 5.0 ANTI DI
Slide 28: Shareholding Pattern
Shareholding Pattern BSE Ticker 543904 1.1% 3.9% 0.8% NSE Symbol MANKIND 17.7% Market Cap. (INR Crore)* 70,213 % Free Float 23.5 Free Float Market Cap. (INR Crore) 16,500 76.5% Shares Outstanding (Crore) 40.06 Industry Pharmaceuticals Promoters FPI & Bodies Corporate Mutual Funds Retail Others Share
Slide 29: Q2 & H1FY24 Earnings Call Details
Q2 & H1FY24 Earnings Call Details Date 1st November, 2023 Time 12:00 PM IST Dial – In Details Universal Access Numbers +91 22 6280 1214 / +91 22 7115 8115 https://services.choruscall.in/DiamondPassRegistration/register?confirm Diamond Pass ationNumber=8760867&linkSecurityString=31912d6244 29
Slide 30: Annexures
Annexures • ROE = (Profit for the year) / (average total equity less cash) o Profit excludes interest income and gain on current investments measured at FVTPL • Adjusted ROE = (Adjusted profit for the year) / (average adjusted total equity less cash) o Profit excludes any M&A related impact, interes
Slide 31: Thank You
Thank You For more information please visit our website: https://www.mankindpharma.com For specific queries, contact: Investor Relations – 011 - 46846700 Investor.relations@mankindpharma.com